Where Science Meets Compassion: How Allison Rosenthal, DO, Is Rewriting the Story of Lymphoma Care – One Patient at a Time When Allison Rosenthal, DO, walks into a patient’s room, she brings with her more than medical expertise. She brings…
Investing in a Cure: Robb Early’s Planned Gift of Hope When Robb Early felt two swollen areas in his groin during a wedding anniversary trip in September 2023, he never imagined the discovery would lead to a cancer diagnosis —…
ASH 2025: Association Between Adolescent and Young Adult (AYA) Age, Acuity of Illness at Diagnosis, and Clinical Trial Enrollment Among Patients with Hematologic Malignancies at a Pediatric Center Clinical trials represent an important opportunity to access cutting edge therapies in…
ASH 2025: Real-World Treatment Patterns, Patient Characteristics, and Outcomes of CBTKI-Based Therapies Amongst a Contemporary Cohort of Patients with R/R MCL in the United States Covalent Bruton tyrosine kinase inhibitors (cBTKis) have been a cornerstone of treatment for relapsed/refractory mantle…
ASH 2025: A Newly Identified Role for IL-5 in Regulating CAR T-associated Toxicity and Efficacy Chimeric antigen receptor (CAR) T-cell therapies have emerged as an important component of the treatment arsenal for B-cell malignancies. Their use, however, has been complicated…
ASH 2025: Sasp-Driven Immune Evasion Defines a Novel African Ancestry-Associated DLBCL Subtype with Distinctive Molecular and Immune Vulnerabilities African Americans with diffuse large B-cell lymphoma (DLBCL) are susceptible to cancer development at an earlier age and worse survival outcomes. Genetics…
ASH 2025: Other Cancers in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma An estimated 1 in 8 people with chronic lymphocytic leukemia (CLL) or small cell leukemia (SLL) develop another type of cancer at some point during their lifetime. This…
ASH 2025: Phase II Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma: 15-year Follow-Up Data from MDACC Trial Several studies have demonstrated the efficacy of lenalidomide plus rituximab, known as R2, in follicular lymphoma (FL). The long-term…
Rare Disease Day: Why Lymphoma — Though Common — Is Still Considered a Rare Cancer Each year on February 28th, Rare Disease Day shines a global spotlight on conditions affecting relatively small patient populations — diseases that often struggle for…
The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib with Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) February 20, 2025 – On February 20, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved acalabrutinib (Calquence, AstraZeneca)…
